DNA Mutation for Beta Thalassaemia in CVS (Form NIBD) at Chughtai Lab

DNA Mutation for Beta Thalassaemia in CVS (Form NIBD) at Chughtai Lab

Beta thalassemia is one of the most prevalent inherited genetic blood disorders in Pakistan, placing a significant clinical and emotional burden on families. The DNA Mutation for Beta Thalassaemia in CVS (Form NIBD) at Chughtai Lab is a highly specialized prenatal diagnostic test designed to identify genetic mutations in the beta-globin (HBB) gene of an unborn fetus. This molecular investigation is performed on chorionic villus sampling (CVS) tissue, which is obtained from the developing placenta during the first trimester of pregnancy, typically between the 10th and 13th weeks of gestation. By analyzing the fetal DNA contained within these placental microvilli, molecular geneticists can determine whether the fetus has inherited beta thalassemia major, carries the beta thalassemia trait (minor), or is entirely unaffected.

The clinical significance of this test cannot be overstated. For carrier couples (where both parents possess the beta thalassemia trait), there is a 25% risk in each pregnancy of having a child with beta thalassemia major—a severe, life-threatening form of anemia requiring lifelong blood transfusions and iron chelation therapy. The DNA Mutation for Beta Thalassaemia in CVS (Form NIBD) at Chughtai Lab provides expectant parents with definitive, early-stage diagnostic clarity. This test utilizes advanced molecular biology techniques, such as Polymerase Chain Reaction (PCR) and Sanger Sequencing or Amplification Refractory Mutation System (ARMS-PCR), to target and identify specific mutations common in the Pakistani population. The inclusion of “Form NIBD” ensures that the clinical referral, parental mutation profiles, and genetic counseling documentation from the National Institute of Blood Diseases are fully integrated, optimizing diagnostic accuracy and ensuring seamless clinical coordination.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure the safety of both the mother and the fetus, as well as the diagnostic accuracy of the molecular analysis. Patients must adhere to the following guidelines:

• Genetic Counseling: It is highly recommended that both parents undergo genetic counseling prior to the procedure to understand the risks, benefits, and implications of the results.
• Parental Reports: Couples must provide their own documented beta thalassemia mutation reports. Knowing the specific parental mutations is critical, as the lab targets these specific genetic sites in the fetal DNA.
• Form NIBD Completion: The official NIBD referral form must be fully completed and signed by the referring hematologist or obstetrician, detailing clinical history and parental genetic profiles.
• Ultrasound Documentation: A recent obstetric ultrasound report (performed within 24-48 hours prior to the CVS) must be submitted to confirm gestational age, fetal viability, and placental localization.
• Consent Forms: Signed informed consent for both the invasive CVS procedure and the genetic testing must be completed.
• Medication Review: Patients must inform their physician of all ongoing medications, particularly blood thinners like aspirin, heparin, or low-molecular-weight heparin, which may need to be temporarily discontinued.
• Maternal Blood Sample: A maternal blood sample (EDTA purple-top tube) is typically collected alongside the CVS sample to rule out maternal cell contamination (MCC), ensuring the analyzed DNA is purely fetal.

During the Procedure

The clinical workflow consists of two primary phases: sample collection by an obstetrician or fetal medicine specialist, followed by advanced molecular analysis at Chughtai Lab.

• Sample Collection (CVS): The invasive procedure is performed under continuous ultrasound guidance. Depending on placental location, the specialist will perform either a transabdominal or transcervical CVS to aspirate a small sample of chorionic villi. Local anesthesia may be administered to minimize discomfort.
• Sample Transport: The collected chorionic villus tissue is immediately placed in a sterile transport medium provided by Chughtai Lab and transported under strict temperature-controlled conditions to the molecular diagnostics division.
• DNA Extraction: In the laboratory, the chorionic tissue is carefully separated from any maternal decidua under a microscope. Fetal DNA is then extracted using high-purity molecular extraction kits.
• Molecular Analysis: The extracted DNA undergoes PCR amplification. Using targeted primers, the laboratory screens for the specific parental mutations using ARMS-PCR or direct DNA sequencing.
• Safety and Quality Control: Chughtai Lab employs stringent quality control protocols, including maternal cell contamination analysis via Short Tandem Repeat (STR) profiling, to guarantee that maternal tissue does not interfere with the fetal genetic reading.

When is a DNA Mutation for Beta Thalassaemia in CVS (Form NIBD) Performed?

Carrier Status in Both Parents

When pre-marital or routine screening reveals that both partners are carriers of the beta thalassemia trait (heterozygous for an HBB gene mutation), they have a high risk of conceiving a child with beta thalassemia major. This test is performed early in pregnancy to determine the genetic status of the fetus, allowing the couple to make informed reproductive and clinical decisions.

Family History of Beta Thalassemia Major

Couples who already have an affected child with transfusion-dependent beta thalassemia major, or who have a documented family history of the disease in close relatives, are prime candidates for this prenatal diagnostic test. The test is requested during the first trimester to evaluate the recurrence risk in the current pregnancy.

Consanguineous Marriages with High Genetic Risk

In regions where consanguineous (first-cousin) marriages are common, the prevalence of autosomal recessive disorders like beta thalassemia is significantly elevated. If family screening indicates carrier status within the family lineage, physicians strongly recommend this targeted prenatal test to prevent the birth of children with severe hemoglobinopathies.

Previous Child Diagnosed with Hemoglobinopathy

For mothers who have had a previous pregnancy affected by beta thalassemia major or compound heterozygous states (such as HbS-Beta Thalassemia or HbE-Beta Thalassemia), this test is routinely prescribed in subsequent pregnancies. It provides early diagnostic confirmation, reducing maternal anxiety and facilitating early clinical planning.

Abnormal Prenatal Screening or Ultrasound Findings

If early prenatal screening or maternal hematological indices suggest a high risk of hemoglobin disorders, or if specific fetal conditions are suspected, obstetricians utilize this molecular test in conjunction with Form NIBD to obtain a definitive genetic diagnosis directly from placental tissue, bypassing the need to wait for amniocentesis in the second trimester.

What Does a DNA Mutation for Beta Thalassaemia in CVS (Form NIBD) Detect?

The molecular analysis of chorionic villus samples at Chughtai Lab is highly precise and is designed to detect a wide array of genetic variations within the HBB gene. Specifically, the test identifies:

• IVS-1-5 (G->C) Mutation: The most common beta-thalassemia mutation in the Pakistani population, leading to severe beta-plus or beta-zero thalassemia phenotypes.
• Frameshift 8-9 (+G): A common mutation causing a premature stop codon and resulting in a beta-zero thalassemia phenotype.
• Frameshift 41-42 (-CTTT): A highly prevalent deletion mutation in South Asia that completely disrupts beta-globin chain synthesis.
• IVS-1-1 (G->T): A splice-site mutation that severely impairs the normal splicing of beta-globin pre-mRNA.
• Deletion 619 bp: A large deletion at the 3′ end of the beta-globin gene, highly characteristic of specific ethnic groups in Pakistan.
• Cap +1 (A->C): A promoter region mutation associated with milder, beta-plus thalassemia traits.
• Frameshift 16 (-C): A microdeletion mutation leading to a shift in the reading frame and complete absence of beta-chain production.
• IVS-2-1 (G->A): A mutation affecting the consensus donor splice site of intron 2, leading to abnormal splicing.
• Codon 30 (G->C): A missense mutation affecting the translation of the beta-globin chain.
• Codon 15 (G->A): A nonsense mutation that halts translation prematurely, leading to non-functional beta-globin.
• Codon 5 (-CT): A frameshift mutation resulting in a truncated, non-functional protein product.
• Homozygous State: Detection of identical mutations on both alleles of the HBB gene, confirming a diagnosis of Beta Thalassemia Major.
• Heterozygous State: Detection of a mutation on only one allele, confirming that the fetus is a healthy carrier (Beta Thalassemia Minor).
• Compound Heterozygosity: Detection of two different mutations on the two HBB alleles (e.g., IVS-1-5 on one allele and Fr 8-9 on the other), which typically results in a severe clinical phenotype.
• Wild-Type Alleles: Absence of any targeted beta-thalassemia mutations, indicating a genetically normal fetus regarding the tested mutations.
• Maternal Cell Contamination (MCC): Identification of maternal DNA presence within the fetal sample, which is critical for validating the accuracy of the fetal results.
• HbS (Sickle Cell) Mutation co-inheritance: Detection of the codon 6 (A->T) mutation in combination with a beta-thalassemia mutation, indicating Sickle-Beta Thalassemia.
• HbE Mutation co-inheritance: Detection of the codon 26 (G->A) mutation, which when combined with beta-thalassemia leads to HbE-Beta Thalassemia.
• Beta-Plus (β+) Thalassemia Alleles: Mutations that allow some production of normal beta-globin chains.
• Beta-Zero (β0) Thalassemia Alleles: Mutations that completely prevent the synthesis of any functional beta-globin chains.
• Unclassified Variants: Rare or novel mutations within the HBB gene sequence that may require further familial segregation analysis.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to delivering highly accurate molecular results within a clinically appropriate timeframe, recognizing the time-sensitive nature of prenatal diagnostics. The turnaround time for the DNA Mutation for Beta Thalassaemia in CVS (Form NIBD) is typically 7 to 10 working days, as the sample must undergo meticulous DNA extraction, PCR amplification, sequencing, and rigorous quality verification. Once the report is finalized by a consultant molecular pathologist, patients receive an automated SMS notification. Reports can be accessed online through the official Chughtai Lab web portal, via the Chughtai Lab mobile application, or collected in person from any of the numerous Chughtai Lab diagnostic centers across Pakistan.

DNA Mutation for Beta Thalassaemia in CVS (Form NIBD) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HBB Gene Allele 1 (Maternal Origin)	Wild-type (No mutation detected)	Presence of beta-thalassemia mutation (e.g., IVS-1-5, Fr 8-9)
HBB Gene Allele 2 (Paternal Origin)	Wild-type (No mutation detected)	Presence of beta-thalassemia mutation (e.g., Fr 41-42, Del 619)
Fetal Genetic Status	Normal (Homozygous Wild-Type)	Beta Thalassemia Minor (Carrier) or Beta Thalassemia Major / Intermedia (Affected)
Maternal Cell Contamination (MCC)	Negative (Pure fetal DNA analyzed)	Positive (Maternal DNA present, requiring sample re-extraction or re-collection)
Beta-Globin Chain Synthesis Potential	Normal functional synthesis	Severely reduced (β+) or completely absent (β0) synthesis
Co-inherited Hemoglobin Variants	Absent	Presence of HbS (Sickle cell trait) or HbE variants
Sample DNA Quality & Quantity	Adequate concentration and high purity	Inadequate DNA yield, degraded sample, or PCR inhibition

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for DNA Mutation for Beta Thalassaemia in CVS (Form NIBD)?

• State-of-the-Art Molecular Biology Lab: Chughtai Lab utilizes advanced PCR and sequencing platforms to ensure the highest analytical sensitivity and specificity for prenatal genetic testing.
• Expert Consultant Pathologists: Reports are analyzed and signed by highly qualified molecular pathologists and geneticists with extensive experience in hemoglobinopathies.
• Strict Quality Control: The laboratory participates in international external quality assurance programs and strictly performs maternal cell contamination testing for all prenatal samples.
• Nationwide Network: With a vast presence across Pakistan, Chughtai Lab offers convenient sample drop-off and coordinate transport services under optimal cold-chain conditions.
• Form NIBD Integration: Seamless processing of NIBD clinical referral forms, ensuring that specialized clinical data is directly integrated into the diagnostic workflow.
• Secure and Confidential Reporting: Patient genetic data is handled with the highest level of confidentiality and security, accessible only to authorized clinical personnel.
• Digital Accessibility: Patients can easily download reports via the Chughtai Lab mobile app or website, reducing the need for physical travel during pregnancy.
• Patient-Focused Care: Dedicated support staff and clear clinical guidelines help ease the anxiety of expectant parents throughout the testing process.